LUTS

NorthShore University HealthSystem offers expanded access to treat most common prostate ailment

Retrieved on: 
Wednesday, August 16, 2023
TURP, University, Anatomy, BPH, Urination, LUTS, Quality of life, Swedish Hospital, Incontinence, Prostate, North, Patient, Standard of care, NorthShore University HealthSystem, Ageing, Erectile dysfunction, FDA, Medical imaging, Nursing, Aquablation therapy, Urology

EVANSTON, Ill., Aug. 16, 2023 (GLOBE NEWSWIRE) -- NorthShore University HealthSystem (NorthShore) and PROCEPT BioRobotics® announce a significant milestone in access to treatment of Benign Prostatic Hyperplasia (BPH).

Key Points: 
  • EVANSTON, Ill., Aug. 16, 2023 (GLOBE NEWSWIRE) -- NorthShore University HealthSystem (NorthShore) and PROCEPT BioRobotics® announce a significant milestone in access to treatment of Benign Prostatic Hyperplasia (BPH).
  • NorthShore will also install a third AquaBeam system at Swedish Hospital on the north side of Chicago.
  • BPH is the most common prostate ailment, affecting nearly 40 million men in the United States, with more than half of men aged 50 and above impacted by the condition.
  • For more information about NorthShore University HealthSystem’s urological services and to schedule an appointment, visit www.northshore.org/urological-health .

Urotronic Announces FDA Approval of Optilume® BPH Catheter System, Pioneering the Next Generation of Minimally Invasive Solutions for Enlarged Prostate Symptom Relief

Retrieved on: 
Tuesday, July 11, 2023
Icahn School of Medicine at Mount Sinai, BPH, Food, Food and Drug Administration, LUTS, Paclitaxel, Quality of life, PINNACLE, Mount Sinai, MIST, Patient, FDA, Urology, Medical device, Medical imaging

Mechanical dilation with Optilume BPH achieves an anterior commissurotomy, while delivery of paclitaxel is intended to maintain luminal patency during healing.

Key Points: 
  • Mechanical dilation with Optilume BPH achieves an anterior commissurotomy, while delivery of paclitaxel is intended to maintain luminal patency during healing.
  • "With the highest reported Qmax in BPH MIST trials to date, Optilume BPH is the next generation of minimally invasive technology, creating a new drug device space among BPH therapies," said Dr. Steven A. Kaplan, professor of urology at the Icahn School of Medicine at Mount Sinai in New York.
  • Optilume BPH is a minimally invasive outpatient procedure engineered to alleviate urinary symptoms caused by BPH, a condition affecting 70% of men 60-69 years of age and 80% of those 70 or older.
  • By combining mechanical dilation with the safe and proven drug paclitaxel, the Optilume BPH Catheter System achieves an anterior commissurotomy, while delivery of paclitaxel is intended to maintain luminal patency during healing.

New Data Highlight that Early Intervention with the UroLift® System Facilitates Long-Term Outcomes for BPH Patients

Retrieved on: 
Wednesday, May 3, 2023
TURP, University, BPH, AUA, Catheter, PUL, LUTS, International Prostate Symptom Score, Quality of life, American Urological Association, PVR, TFX, Research, Prostate, Prostatic urethral lift, MIST, NYSE, Lower urinary tract symptoms, MD, Patient, Urology, Urinary retention, Annual general meeting, PVP, Cystoscopy, PSA, IPSS, Disease, Medical imaging, Nursing

PUL with the UroLift® System was durable in most subjects at one and five years.

Key Points: 
  • PUL with the UroLift® System was durable in most subjects at one and five years.
  • In surgical therapy patients, procedure complication rates were lowest for the UroLift® System (17%) and highest for Rezūm™ (28%).
  • “As clinicians listen to their patients’ goals, technological advances are allowing them to deliver treatments that reflect those priorities better than ever before.
  • The data presented at AUA reinforce the importance of earlier intervention in BPH and the UroLift® System as an effective and durable BPH solution that improves patients’ quality of life and supports a superior patient experience.”1-3

TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting

Retrieved on: 
Monday, May 1, 2023
Prostate cancer, Comparison, McCormick Place, BPH, AUA, LUTS, Clinical trial, Cancer, American Urological Association, Prostate, Patient, United States Army Medical Corps, Annual general meeting, Fellow, Pivotal, TSX, University of Oslo, Prostatectomy, Erectile dysfunction, Safety, Level 1, Johns Hopkins School of Medicine, Pharmaceutical industry, Medical imaging

TORONTO, May 01, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the presentation of four studies of the Transurethral Ultrasound Ablation (“TULSA”) procedure at the American Urological Association (“AUA”) 2023 Annual Meeting, which took place from April 28 - May 1, 2023 at McCormick Place in Chicago, Illinois.

Key Points: 
  • The data demonstrate that both oncological control and functional outcomes are durable to four years after treatment with TULSA.
  • Urinary function was durable over the four-year follow-up period, with 99% of patients preserving urinary continence (≤1 pad/day) and 94% remaining completely pad-free.
  • At follow-up, oncological success was 88%, with 85% of men with LUTS before treatment experiencing relief after treatment with TULSA.
  • There were two Grade 4 complications - one after HIFU ablation and one after RALP - but none after TULSA.

Urotronic Announces Presentation of Data from Two Clinical Trials Evaluating Optilume® BPH System's Effectiveness and Durability

Retrieved on: 
Monday, May 1, 2023
Male, Icahn School of Medicine at Mount Sinai, BPH, Food, AUA, Urethral stricture, CE marking, LUTS, International Prostate Symptom Score, Paclitaxel, Quality of life, American Urological Association, PINNACLE, Food and Drug Administration, Mount Sinai, Sale, MIST, U.S. FDA, High, Lower urinary tract symptoms, Patient, Randomness, Trial of the century, FDA, Urology, IPSS, Medical imaging, Medical device, Pharmaceutical industry, Spirometry

MINNEAPOLIS, May 1, 2023 /PRNewswire/ -- Urotronic, Inc., a Minnesota-based medical device company pioneering the application of its drug-coated balloon technology for use in interventional urology, today announced the presentation of positive data from two clinical trials evaluating the Optilume® BPH System's effectiveness and durability in treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Four-year and 12-month data from the EVEREST and PINNACLE clinical trials were presented by Dr. Steven A. Kaplan, professor of urology at the Icahn School of Medicine at Mount Sinai in New York and the principal investigator of the two studies, during the American Urological Association's (AUA) Annual Meeting in Chicago.

Key Points: 
  • "The positive data from the PINNACLE and EVEREST trials – including the highest reported Qmax in BPH MIST trials to date – demonstrates clear and compelling sustained clinical outcomes through four years post-treatment," said Dr. Kaplan.
  • "Optilume BPH is not your grandfather's BPH balloon – it's the next generation of minimally invasive technology, creating a new drug device space among BPH therapies."
  • Mechanical dilation with Optilume BPH achieves an anterior commissurotomy, while delivery of paclitaxel is intended to maintain luminal patency during healing.
  • The highest average peak urinary flow rate (Qmax) at 12 months reported in randomized MIST trials for BPH.

PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates

Retrieved on: 
Monday, April 3, 2023
Contraindication, BPH, Policy, LUTS, FDA, Health, Pharmaceutical industry, Aquablation therapy, UnitedHealth Group

The updated policy follows Aquablation’s FDA label and is effective June 1, 2023.

Key Points: 
  • The updated policy follows Aquablation’s FDA label and is effective June 1, 2023.
  • United Healthcare is the largest health insurance company in the United States with over 45 million covered lives.
  • “We are very excited to announce the updated policy from United Healthcare and believe this will greatly improve accessibility of Aquablation therapy for men suffering from BPH.” said Reza Zadno, President and CEO.
  • “With the addition of United Healthcare, we estimate approximately 95% of all men in the United States now have access to Aquablation therapy.”
    United Healthcare’s updated BPH coverage policy can be found here:

New Year - New Advanced Technology for Cineo StageLynx App!

Retrieved on: 
Thursday, January 12, 2023
News, Quantum, LUTS, Comcast, Environment, Marketing, Reflex, Apple, Light, Television, NBCUniversal, R15, Mobile phone, 167P/CINEOS

LOS ANGELES, Jan. 12, 2023 /PRNewswire/ -- Cineo Lighting (www.cineolighting.com), an industry leader in innovative production technology lighting, released their new and improved Cineo StageLynx App (version 3.2.4a) on the Apple and Google Play App stores for mobile, tablet, or desktop use.

Key Points: 
  • Designed for lighting professionals, the Cineo StageLynx App provides a seamless user experience when controlling or testing each Cineo light.
  • "The Cineo StageLynx App was developed to be identical to the built-in console on our lighting instruments.
  • The inventive Cineo StageLynx App features the ability to control presets, effects, and LUTS from across the room without having to touch the light.
  • Cineo Stagelynx is standard on the Quantum series, LB800 and Reflex R15, the StageLynx operating system will be standard on all future lighting products.

PROCEPT BioRobotics Corp. to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, December 14, 2022
Conference, BPH, Health, LUTS, Prostate, Pacific Time Zone, Benign prostatic hyperplasia, Medical device, Medical imaging, Aquablation therapy

REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference.
  • Management is scheduled to present on Tuesday, January 10 at 9:45 a.m. Pacific Time.
  • A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com .
  • PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology.

Belgian Company Minze Health Raises €3.9m to Further Scale Its Digital Health Solutions for the Treatment of Urinary Tract Problems

Retrieved on: 
Thursday, December 1, 2022
Managed Care, Men, Other Health, General Health, Internet, Consumer, Apps, Applications, Technology, Medical Devices, Biotechnology, Women, Seniors, Health, Growth, Urinary incontinence, RPM, LUTS, Digital, Pelvic floor, New Senior Investment Group, Prevalence, AI, Multimedia, Hospital, Medtech, Patient, Executive Committee, Social Problems, Ageing, Prostate, PMV, Capricorn, Health, Therapy, Quality of life, Lower urinary tract symptoms, Remote patient monitoring, Worldwide, Health insurance, Medical device, Online shopping, Nirmal Minz

View the full release here: https://www.businesswire.com/news/home/20221201005062/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221201005062/en/
    Minze Diary, a novel and automated bladder diary enabling quicker and better treatment of LUTS.
  • (Photo: Minze Diary)
    Minze Health is a digital healthcare scale-up that enables better care for 2.3 billion people with Lower Urinary Tract Symptoms (LUTS).
  • Most common symptoms are urinary incontinence, a weak urine stream due to an enlarged prostate, frequent voiding and night voiding.
  • Tine Bekaert, Senior Investment Manager at PMV: Minze Healths solutions to often unspoken social problems, represent enormous international potential.

PROCEPT BioRobotics Reports Third Quarter 2022 Financial Results and Increases 2022 Revenue Guidance

Retrieved on: 
Thursday, November 3, 2022
Man, Annual report, Company, BPH, Research, Growth, International, Investment, GAAP, GLOBE, Form 10-K, Webcast, EBITDA, COVID-19, Benign prostatic hyperplasia, Nasdaq, Tax, LUTS, Health, U.S. Securities and Exchange Commission, Forward-looking statement, Providence, Security (finance), Multi-system (rail), Depreciation, SEC, Achievement, Biorobotics, Patient, Prostate, Solution, Medical device, Video game, Pharmaceutical industry, Bookkeeping, Broadcasting, Risk management, Aquablation therapy

Revenue for the third quarter of 2022 was $20.3 million, an increase of 135% compared to the prior year period.

Key Points: 
  • Revenue for the third quarter of 2022 was $20.3 million, an increase of 135% compared to the prior year period.
  • The increase was primarily driven by U.S revenues, including both system sales to new hospital customers and increased handpiece revenue.
  • U.S. handpiece and consumable revenue for the quarter was $8.0 million, an increase of 267% compared to the prior year period.
  • Operating expenses in the third quarter of 2022 were $32.3 million, compared with $17.0 million in the prior year period.